Clinical Trial

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia

Study acronym: ENERGIZEKids
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-04
Trial Details
NCT Number NCT07517133
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Enrollment 45 participants
Start Date 2026-09
Primary Completion 2029-03 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-03